What Happened to Rubella (German Measles)?
Rubella, commonly known as German Measles, is a viral infection that once caused widespread outbreaks and severe birth defects through Congenital Rubella Syndrome (CRS). Thanks to the development and widespread adoption of the rubella-containing vaccine (RCV), often administered as part of the MMR vaccine, the disease has been eliminated in many regions globally. However, despite significant progress, recent years have seen resurgences in cases in some areas due to immunity gaps and vaccine hesitancy, highlighting the ongoing need for sustained vaccination efforts.
Quick Answer
Rubella, or German Measles, has seen a dramatic decline globally due to widespread vaccination efforts, with 117 countries verified as having eliminated the disease by 2024. The Americas became the first WHO region to eliminate endemic rubella transmission in 2015. However, recent years, including 2025 and 2026, have witnessed localized outbreaks and resurgences in reported cases in several countries, particularly in regions with lower vaccination coverage like parts of Africa, and even in countries like South Africa, Chad, and Nigeria during vaccine rollout. Global efforts continue to push for worldwide elimination by strengthening immunization programs and addressing persistent immunity gaps.
📊Key Facts
📅Complete Timeline15 events
Rubella First Described
German physicians first describe rubella as a distinct disease, leading to its common name 'German Measles'.
Link to Congenital Rubella Syndrome (CRS) Discovered
Australian ophthalmologist Norman Gregg observes a link between maternal rubella infection during pregnancy and congenital cataracts in infants, establishing the concept of CRS.
Major Rubella Epidemic in the U.S.
A widespread rubella epidemic sweeps through the United States, resulting in an estimated 12.5 million cases, 2,000 cases of encephalitis, 11,250 therapeutic or spontaneous abortions, 2,100 neonatal deaths, and 20,000 infants born with CRS.
Rubella Vaccine Licensed in the U.S.
The first rubella vaccine is licensed in the United States, marking a critical step towards controlling the disease and preventing CRS.
Introduction of MMR Vaccine
The combined Measles, Mumps, and Rubella (MMR) vaccine is introduced, simplifying immunization schedules and improving coverage for rubella.
Rubella Declared Eliminated in the United States
The United States achieves rubella elimination status, meaning the sustained absence of endemic transmission for at least 12 months.
WHO Region of the Americas Declared Rubella-Free
The Region of the Americas becomes the first in the world to be declared free of endemic transmission of rubella by the World Health Organization.
WHO Recommends Universal RCV Introduction
The World Health Organization recommends the introduction of rubella-containing vaccine (RCV) in all countries, and its Strategic Advisory Group of Experts drops the condition that countries must first achieve high measles vaccination coverage.
Global RCV Coverage Reaches 73%
Estimated global coverage with a rubella-containing vaccine (RCV) among infants aged 12–23 months increases to 73%, and 117 countries are verified as having eliminated rubella.
Eastern Mediterranean Region Adopts Elimination Goal
The Eastern Mediterranean Region adopts a regional rubella elimination goal, meaning all six WHO regions now have formal targets for rubella elimination.
Nepal Eliminates Rubella
The World Health Organization announces that Nepal has eliminated rubella as a public health problem, a significant achievement for the country.
Nigeria Begins Integrated Vaccination Campaign
Nigeria launches an integrated measles, rubella, and polio vaccination campaign, aiming to reach approximately 106 million children, with its southern phase commencing in January 2026.
Rubella Outbreak in South Africa
South Africa reports 398 laboratory-confirmed rubella cases through its national fever-rash surveillance system during this period, primarily among children aged 1–14 years.
Measles & Rubella Partnership Operational Strategy 2026–2030 Released
The Measles & Rubella Partnership releases its Operational Strategy for 2026–2030, highlighting that the world remains off track for measles and rubella elimination by 2030 due to persistent immunity gaps and increasing outbreaks, and outlining actionable approaches.
U.S. Measles Elimination Status Under Review
The Pan American Health Organization (PAHO) Measles and Rubella Elimination Regional Monitoring and Re-Verification Commission is scheduled to review the United States' measles elimination status, with concerns that it is 'highly likely' to be lost due to recent outbreaks.
🔍Deep Dive Analysis
Rubella, a contagious viral infection, was once a common childhood disease, but its most devastating impact was on unborn babies, leading to Congenital Rubella Syndrome (CRS). CRS can cause severe birth defects such as deafness, vision problems, heart defects, and intellectual disabilities. Before the introduction of the vaccine, an estimated 100,000 infants were born with CRS annually worldwide.
The turning point came with the development of the rubella vaccine, first licensed in 1969, and its subsequent inclusion in the measles, mumps, and rubella (MMR) vaccine. This safe and effective vaccine provides long-lasting immunity, similar to natural infection. The United States declared rubella eliminated in 2004, and the WHO Region of the Americas achieved the milestone of eliminating endemic rubella transmission in 2015, a global first.
Global vaccination efforts have led to substantial progress. By 2024, 179 of 194 countries (92%) had introduced a rubella-containing vaccine (RCV) into their routine immunization schedules, up from 132 countries in 2012. Global coverage with the first dose of RCV among infants aged 12–23 months increased from 39% in 2012 to 73% in 2024. This has resulted in a significant reduction in CRS cases, estimated to have declined by more than 70% from approximately 101,000 cases in 2012 to 27,000 in 2024.
Despite these successes, the path to global rubella elimination faces ongoing challenges. The number of countries verified as having eliminated rubella reached 117 (60%) by 2024, but elimination status varies widely by region, with the African Region having the lowest RCV coverage at 37% in 2024. Reported rubella cases globally, after decreasing significantly, saw an increase from 18,881 in 2022 to 31,593 in 2024. This resurgence was largely driven by transmission in countries like Chad and Nigeria, which had not introduced RCV, and in South Africa during its RCV rollout.
Recent developments in 2025 and 2026 underscore the dynamic nature of elimination efforts. In August 2025, Nepal was declared by the WHO to have eliminated rubella as a public health problem, becoming the sixth country in the WHO South-East Asia Region to achieve this. The Eastern Mediterranean Region also adopted a regional rubella elimination goal in 2025, meaning all six WHO regions now have formal targets. Nigeria and the Democratic Republic of the Congo (DRC) have been introducing the vaccine during 2025 and 2026, which is expected to substantially reduce the number of unvaccinated infants in the African region. However, South Africa reported 398 laboratory-confirmed rubella cases between December 2025 and July 2026, indicating ongoing outbreaks. The Measles & Rubella Partnership's Operational Strategy for 2026–2030 emphasizes proactive prevention of outbreaks, addressing immunity gaps, and overcoming funding shortfalls to achieve the 2030 elimination targets.
What If...?
Explore alternate histories. What if Rubella (German Measles) made different choices?